natgillin/translations-raw huggingface dataset:
Lactic acidosis is a very rare but serious metabolic complication that can occur due to metformin accumulation.
Laktacidoza je vrlo rijetka, ali ozbiljna metabolička komplikacija koja se može pojaviti zbog nakupljanja metformina.
Lactic acidosis is a very rare, but serious (high mortality in the absence of prompt treatment), metabolic complication that can occur due to metformin accumulation.
Laktacidoza je vrlo rijetka, ali ozbiljna (smrtnost je visoka ako se odmah ne započne liječenje) metabolička komplikacija koja može nastupiti zbog nakupljanja metformina.
Lactic acidosis is a very rare, but serious (high mortality in the absence of prompt treatment), metabolic complication that can occur due to metformin accumulation.
Laktacidoza je vrlo rijetka, ali ozbiljna metabolička komplikacija (s visokom smrtnošću ako se pravodobno ne liječi) koja može nastupiti zbog akumulacije metformina.
Lactic acidosis is a very rare, but serious (high mortality in the absence of prompt treatment), metabolic complication that can occur due to metformin, a component of this medicinal product, accumulation.
Laktacidoza je vrlo rijetka, ali ozbiljna metabolička komplikacija (s visokom smrtnošću ako se pravodobno ne liječi) koja može nastupiti zbog nakupljanja metformina, sastojka ovog lijeka.
Lactic acidosis is a very rare, but serious (high mortality rate in the absence of prompt treatment), metabolic complication that can occur due to metformin accumulation.
Laktacidoza je vrlo rijetka, ali ozbiljna (visoka stopa smrtnosti u odsustvu brzog liječenja) komplikacija metabolizma, koja se može pojaviti zbog nakupljanja metformina.
Lactic acidosis is a very rare, but serious, metabolic complication that can occur due to metformin accumulation.
Laktacidoza je vrlo rijetka, ali ozbiljna metabolička komplikacija koja može nastati zbog nakupljanja metformina.
Lactic acidosis is caused by a build-up of lactic acid in the body.
Laktacidoza nastaje nakupljanjem mliječne kiseline u tijelu.
Lactic acidosis is characterised by acidotic dyspnea, abdominal pain and hypothermia followed by coma.
Laktacidoza je karakterizirana acidoznom dispnejom, boli u abdomenu i hipotermijom nakon čega slijedi koma.
Lactic acidosis is characterised by acidotic dyspnoea, abdominal pain and hypothermia followed by coma.
Laktacidozu karakterizira acidozna dispneja, bol u trbuhu i hipotermija praćena komom.
Lactic acidosis is characterised by acidotic dyspnoea, abdominal pain and hypothermia followed by coma.
Simptomi laktacidoze obuhvaćaju dispneju, bol u abdomenu i hipotermiju s komom.
Lactic acidosis is characterised by acidotic dyspnoea, abdominal pain and hypothermia followed by coma.
Simptomi laktacidoze obuhvaćaju dispneju, bol u trbuhu i hipotermiju s komom.
Lactic acidosis is further characterised by acidotic dyspnoea and hypothermia followed by coma.
Laktacidozu nadalje karakteriziraju acidozna dispneja i hipotermija, nakon kojih slijedi koma.
Lactic acidosis is more likely to develop in people who have liver disease, or in obese (very overweight) people, especially women.
Laktacidoza će se prije javiti u ljudi koji imaju bolest jetre ili koji su pretili (imaju izrazito prekomjernu tjelesnu težinu), a posebno kod žena.
Lactic acidosis is more likely to happen in people who have liver problems, or in people who are very overweight, especially women.
Veća je vjerojatnost da će se laktacidoza razviti u osoba koje imaju tegobe s jetrom ili u osoba koje imaju znatno prekomjernu tjelesnu težinu, osobito u žena.
Lactic acidosis occurs more often in women – particularly if they are overweight and in people with liver disease.
Laktacidoza nastaje češće u žena – osobito u onih s prekomjernom tjelesnom težinom i u osoba s bolešću jetre.
Lactic acidosis occurs more often in women – particularly if they are overweight, and in people with liver disease.
Laktacidoza nastaje češće u žena – osobito u onih s prekomjernom tjelesnom težinom – i u osoba s bolešću jetre.
Lactic acidosis occurs more often in women, particularly if they are overweight, and in people with liver disease.
Laktacidoza se češće javlja u žena, osobito ako imaju prekomjernu tjelesnu težinu, te u osoba s jetrenom bolešću.
Lactic acidosis occurs more often in women, particularly if they are very overweight.
Laktacidoza se pojavljuje češće u žena, osobito u onih koje su izrazito pretile.
Lactic acidosis, usually associated with hepatomegaly and hepatic steatosis, has been reported with the use of zidovudine .
Laktacidoza, obično udružena s hepatomegalijom i hepatalnom steatozom zabilježena je prilikom primjene zidovudina.
Lactic acidosis, Vitamin B12 deficiencya
Laktacidoza, deficijencija vitamina B a
Lactic acidosis: 0.03 cases/1000 patient-years (see section 4.4).
Laktacidoza: 0,03 slučaja/1000 bolesnik-godina (vidjeti dio 4.4).
Lactic acidosis: lactic acidosis, usually associated with hepatomegaly and hepatic steatosis has been reported with the use of stavudine.
Laktacidoza: kod primjene stavudina opisana je laktična acidoza, obično povezana s hepatomegalijom i steatozom.
Lactobacillus, Leuconostoc and Pediococcus that are intrinsically resistant to glycopeptides.
Lactobacillus, Leuconostoc i Pediococcus koji su intrinzično rezistentni na glikopeptide.
Lactose (160 mg/film-coated tablet) and soya lecithin (0.26 mg/film-coated tablet).
Laktoza (160 mg/filmom obloženoj tableti) i sojin lecitin (0,26 mg/ filmom obloženoj tableti).
Lactose (anhydrous), Microcrystalline cellulose, Povidone,
laktoza (bezvodna), celuloza, mikrokristalična, povidon,
Lactose (monohydrate), Magnesium stearate.
celuloza, mikrokristalična, karmelozanatrij, umrežena, povidon, laktoza hidrat, magnezijev stearat.
Lactose (one type of sugar).
laktozu (jednu vrstu šećera).
Lactose anhydrous Magnesium stearate
betadeks laktoza, bezvodna magnezijev stearat
Lactose anhydrous Microcrystalline cellulose Hydroxypropylcellulose Croscarmellose sodium Magnesium stearate
laktoza, bezvodna celuloza, mikrokristalična hidroksipropilceluloza karmelozanatrij, umrežena magnezijev stearat
Lactose intolerance
Netolerancija laktoze
Lactose intolerance: Invirase 200 mg capsules contain lactose.
Nepodnošenje laktoze: Invirase 200 mg kapsule sadrže laktozu.
Lactose monohydrate
Laktoza hidrat
Lactose monohydrate (see section 2 ‘Zoely contains lactose’), microcrystalline cellulose (E460), crospovidone (E1201), talc (E553b), magnesium stearate (E572) and colloidal anhydrous silica Tablet coat (white active film-coated tablets):
Laktoza hidrat (vidjeti u dijelu 2 'Zoely sadrži laktozu'), mikrokristalična celuloza (E460), krospovidon (E1201), talk (E553b), magnezijev stearat (E572) i koloidni, bezvodni silicijev dioksid.
Lactose monohydrate (see section 2)
Laktoza hidrat (vidjeti dio 2.)
Lactose monohydrate Cellulose microcrystalline Hypromellose Magnesium stearate Sodium starch glycolate
laktoza monohidrat celuloza, mikrokristalična hipromeloza magnezijev stearat natrijev škrobni glikolat
Lactose monohydrate Cellulose, microcrystalline Crospovidone
Laktoza monohidrat Mikrokristalična celuloza Krospovidon
Lactose monohydrate Cellulose, microcrystalline Hydroxypropylcellulose (E463) Crospovidone (type A) Hydrogenated castor oil Sodium laurilsulfate
laktoza hidrat celuloza, mikrokristalična hidroksipropil celuloza (E463) krospovidon (tip A) ricinusovo ulje, hidrogenirano natrijev laurilsulfat
Lactose monohydrate Cellulose, microcrystalline Hydroxypropylcellulose (E463) Crospovidone (type A) Hydrogenated vegetable oil Sodium laurilsulfate
laktoza hidrat celuloza, mikrokristalična hidroksipropilceluloza (E463) krospovidon (tip A) hidrogenirano biljno ulje natrijev laurilsulfat
Lactose monohydrate Cellulose, microcrystalline Maize starch Croscarmellose sodium Hypromellose
celuloza, mikrokristalična kukuruzni škrob karmelozanatrij, umrežena hipromeloza
Lactose monohydrate Crospovidone type A Cellulose, microcrystalline Povidone
laktoza hidrat krospovidon tip A celuloza, mikrokristalična povidon
Lactose monohydrate Hydroxypropylcellulose (E463) Croscarmellose sodium Magnesium stearate (E572)
laktoza hidrat hidroksipropilceluloza (E463) karmelozanatrij, umrežena magnezijev stearat (E572)
Lactose monohydrate Hydroxypropylcellulose Crospovidone type A Silica colloidal anhydrous Microcrystalline cellulose Magnesium stearate
hidroksipropilceluloza krospovidon vrste A silicijev dioksid, koloidni, bezvodni celuloza, mikrokristalična magnezijev stearat
Lactose monohydrate Hypromellose (E464) Croscarmellose sodium (E468)
laktoza hidrat hipromeloza (E464) karmelozanatrij, umrežena (E468)
Lactose monohydrate Hypromellose (E464) Titanium dioxide (E171) Iron oxide yellow (E172) Triacetin
Film ovojnica: laktoza hidrat hipromeloza (E464) titanijev dio-ksid (E171) željezov oksid žuti (E172) triacetin
Lactose monohydrate Hypromellose (E464) Titanium dioxide (E171) Iron oxide yellow (E172) Triacetin
Film ovojnica: laktoza hidrat hipromeloza (E464) titanijev dio-ksid (E171, željezov oksid žuti (E172) triacetin
Lactose monohydrate Hypromellose (E464) Titanium dioxide (E171) Iron oxide yellow (E172) Triacetin
Film ovojnica: laktoza hidrat hipromeloza (E464) titanijev dioksid (E171) željezov oksid, žuti (E172) triacetin
Lactose monohydrate Hypromellose (E464) Titanium dioxide (E171) Triacetin (E1518) Yellow iron oxide (E172)
Film ovojnica: laktoza hidrat hipromeloza (E464) titanijev dioksid (E171) triacetin (E1518) željezov oksid, žuti (E172)
lactose monohydrate hypromellose triacetin titanium dioxide (E171) iron oxide yellow (E172) iron oxide red (E172) talc
Film ovojnica laktoza hidrat hipromeloza triacetin titanijev dioksid (E171) željezov oksid žuti (E172) željezov oksid crveni (E172) talk
Lactose monohydrate Macrogol 4000 Hypromellose Titanium dioxide
Film ovojnica: laktoza hidrat makrogol 4000 hipromeloza titanijev dioksid
Lactose monohydrate Macrogol Magnesium stearate Talc
laktoza hidrat makrogol magnezijev stearat talk
Lactose monohydrate Magnesium stearate
laktoza hidrat magnezijev stearat
Lactose monohydrate Magnesium stearate Maize starch Meglumine
laktoza hidrat magnezijev stearat škrob, kukuruzni meglumin
Lactose monohydrate Maize starch
Tablični popis nuspojava
Lactose monohydrate Maize starch Hypromellose Polysorbate 20 Microcrystalline cellulose Croscarmellose sodium
laktoza hidrat kukuruzni škrob hipromeloza polisorbat 20
Lactose monohydrate Maize starch Microcrystalline cellulose Hydroxypropyl cellulose Magnesium stearate
laktoza hidrat kukuruzni škrob celuloza, mikrokristalična hidroksipropilceluloza magnezijev stearat
Lactose monohydrate Microcristalline cellulose Artificial meat flavour Crospovidone
Laktoza monohidrat Mikrokristalinična celuloza
Lactose Monohydrate Microcrystalline Cellulose Chartor Hickory Smoke Flavour Hydroxypropyl Cellulose Croscarmellose Sodium Magnesium Stearate
Laktoza monohidrat Mikrokristalna celuloza Chartor Hickory dimni okus Hidroksipropilna celuloza Kroskarmelozni natrij Magnezijev stearat
Lactose monohydrate Microcrystalline cellulose Croscarmellose sodium Hypromellose
celuloza, mikrokristalična karmelozanatrij, umrežena hipromeloza silicijev dioksid magnezijev stearat
Lactose monohydrate Microcrystalline cellulose Croscarmellose sodium Silica colloidal anhydrous Hypromellose
celuloza, mikrokristalična karmelozanatrij, umrežena
Lactose monohydrate Microcrystalline cellulose Hydroxypropylcellulose Croscarmellose sodium Colloidal anhydrous silica Magnesium stearate
celuloza mikrokristalična hidroksipropilceluloza karmelozanatrij, umrežena silicijev dioksid, koloidni, bezvodni magnezijev stearat
Lactose monohydrate Microcrystalline cellulose Sodium starch glycolate Colloidal anhydrous silica Magnesium stearate
celuloza, mikrokristalična natrijev škroboglikolat silicijev dioksid, koloidni, bezvodni magnezijev stearat
Lactose monohydrate Povidone K25 Crospovidone Sodium laurylsulfate Macrogol 400
Monohidrat laktoze Povidon K25 Krospovidon Natrijev laurilsulfat Makrogol 400
Lactose monohydrate Povidone K30 Croscarmellose sodium Magnesium stearate
laktoza hidrat povidon K30 karmelozanatrij, umrežena magnezijev stearat
Lactose monohydrate Titanium dioxide (E171) Indigo carmine (E132)
laktoza hidrat titanijev dioksid (E171) indigotin (E132)
lactose monohydrate, hypromellose, triacetin, titanium dioxide (E171), iron oxide yellow (E172), iron oxide red (E172), talc.
Film ovojnica: laktoza hidrat, hipromeloza, triacetin, titanijev dioksid (E171), željezov oksid, žuti (E172), željezov oksid, crveni (E172), talk.
lactose monohydrate, hypromellose, triacetin, titanium dioxide (E171), iron oxide yellow (E172), talc.
Film ovojnica: laktoza hidrat, hipromeloza, triacetin, titanijev dioksid (E171), željezov oksid žuti (E172), talk.
Lactose monohydrate, Magnesium stearate.
laktoza hidrat magnezijev stearat
Lactose monohydrate, Maize starch Hydroxypropyl cellulose Magnesium stearate
hidroksipropil celuloza magnezijev stearat
lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate in the tablet core; and polyvinyl alcohol, titanium dioxide, macrogol and talc in the film-coating.
laktoza hidrat, mikrokristalična celuloza, umrežena karmelozanatrij i magnezijev stearat u jezgri tablete; te poli(vinilni) alkohol, titanijev dioksid, makrogol i talk u film ovojnici
Lactose monohydrate, tartaric acid, hydrochloric acid, sodium hydroxide
Laktoza hidrat, tartaratna kiselina, kloridna kiselina, natrijev hidroksid.
Lactose monohydrate.
laktoza hidrat
Lactose monohydrate: 141.5 mg per tablet.
Laktoza hidrat: 141,5 mg po tableti.
Lactose monohydrate: 214 mg per tablet.
Laktoza hidrat: 214 mg po tableti.
Lactose monohydrate: 283 mg per tablet.
Laktoza hidrat: 283 mg po tableti.
Lactose Phosphate buffer Chloride buffer
Laktoza, Fosfatni pufer, Kloridni pufer,
Lactose: This medicinal product contains lactose.
Laktoza: Ovaj lijek sadržava laktozu.
LAL enzyme activity leads to reductions in liver fat content and transaminases, and enables metabolism of cholesteryl esters and triglycerides in the lysosome, leading to reductions in low- density lipoprotein (LDL) cholesterol and non-high-density lipoprotein (HDL) cholesterol, triglycerides, and increases in HDL cholesterol.
Nadomještanje enzimske aktivnosti LAL-a dovodi do smanjenja količine masti u jetri i transaminaza, omogućuje metabolizam kolesterolskih estera i triglicerida u lizosomima i tako uzrokuje smanjenje LDL kolesterola i kolesterola koji nije HDL, triglicerida te povećanje HDL kolesterola.
Lambert-Eaton myasthenic syndrome is a very rare disorder.
Lambert-Eatonov mijastenički sindrom je vrlo rijedak poremećaj.
Lamivudine
(N=177)
Lamivudine 100 mg (n = 207)1
Lamivudin 100 mg (n = 207)1
Lamivudine 100 mg (n = 386)1
Lamivudin 100 mg (n = 386)1
Lamivudine 150 mg BID
150 mg 2x/dan
Lamivudine 150 mg BID (maraviroc 300 mg BID)
Lamivudin 150 mg 2x dnevno (maravirok 300 mg 2x dnevno)
Lamivudine 4 mg/kg Twice- Daily Dosing
geometrijskih
lamivudine adefovir dipivoxil
lamivudin adefovirdipivoksil
Lamivudine and
Cmin: NI
Lamivudine and Truvada should not be administered concomitantly (see section 4.4).
Lamivudin i Truvada ne smiju se primjenjivati istovremeno (vidjeti dio 4.4).
Lamivudine and Viramune can be co- administered without dose adjustments.
istodobno primjenjivati bez
Lamivudine and Viramune can be co- administered without dose adjustments.
Lamivudin i Viramune se mogu istodobno primjenjivati bez prilagodbe doze.
Lamivudine and zidovudine have been widely used as components of antiretroviral combination therapy with other antiretroviral agents of the same class (NRTIs) or different classes (PIs, non- nucleoside reverse transcriptase inhibitors).
Lamivudin i zidovudin se široko primjenjuju kao komponente u kombiniranoj antiretrovirusnoj terapiji s drugim antiretrovirusnim lijekovima iste skupine (nukleozidni inhibitori reverzne transkriptaze) ili drugih skupina (inhibitori proteaze, nenukleozidni inhibitori reverzne transkriptaze).
Lamivudine and/or Raltegravir (alone or in combination with other ART)*
Lamivudin i/ili raltegravir (sami ili u kombinaciji s drugim ART-om)
lamivudine AUC 40 %
lamivudin AUC 40
Lamivudine AUC12: ↔ 1.13 Lamivudine Cmax: ↔ 1.16 Maraviroc concentrations not measured, no effect is expected.
Lamivudin AUC12:  1,13 Lamivudin Cmax:  1,16 Koncentracije maraviroka nisu određivane, učinak nije očekivan.
Lamivudine AUC: 
AUC lamivudina: 
Lamivudine belongs to a group of medicines called nucleoside analogue reverse transcriptase inhibitors (NRTIs)
Lamivudin pripada skupini lijekova koji se zovu nukleozidni analozi inhibitora reverzne transkriptaze (NRTI)
Lamivudine Cmin: 
Cmin lamivudina: 
Lamivudine demonstrates low cytotoxicity to peripheral blood lymphocytes, to established lymphocyte and monocyte-macrophage cell lines, and to a variety of bone marrow progenitor cells in vitro.
Lamivudin pokazuje nisku citoksičnost prema perifernim limfocitima, prema diferenciranim staničnim linijama limfocita i monocita–makrofaga i prema brojnim progenitornim stanicama koštane srži u in vitro uvjetima.
Lamivudine demonstrates low cytotoxicity to peripheral blood lymphocytes, to established lymphocyte and monocyte-macrophage cell lines, and to a variety of bone marrow progenitor cells in vitro.
Lamivudin pokazuje nisku citotoksičnost prema perifernim limfocitima, prema diferenciranim linijama limfocita i monocita – makrofaga i prema brojnim pretečama stanica koštane srži u in vitro uvjetima.
Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays limited binding to the major plasma protein albumin (< 16% - 36% to serum albumin in in vitro studies).
U terapijskom rasponu doziranja lamivudin ima linearnu farmakokinetiku i slabo se veže na albumin, glavni protein u plazmi (<16 – 36% na serumski albumin u in vitro ispitivanjima).
Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays limited binding to the major plasma protein albumin (< 36 % serum albumin in vitro).
Lamivudin pokazuje linearnu farmakokinetiku u rasponu terapijskih doza i ograničeno se veže za glavni protein u plazmi, albumin (< 36% albumina u serumu in vitro).
Lamivudine has been administered to children (2 years and above) and adolescents with compensated chronic hepatitis B. However, due to limitations of the data, the administration of lamivudine to this patient population is not currently recommended (see section 5.1).
Lamivudin je primjenjivan u djece (u dobi od 2 godine i više) i adolescenata s kompenziranim kroničnim hepatitisom B. Međutim, zbog ograničenih podataka zasad se ne preporučuje primjena lamivudina u toj populaciji bolesnika (vidjeti dio 5.1).
Lamivudine has not shown any genotoxic activity in in vivo studies at doses that gave plasma concentrations up to 40-50 times higher than clinical plasma levels.
Lamivudin nije pokazao genotoksičnu aktivnost u studijama in vivo pri dozama koje uzrokuju 40-50 puta više koncentracije u plazmi u odnosu na koncentraciju koja se postiže pri terapijskim dozama lijeka.
Lamivudine in the fixed- dose combination tablet was bioequivalent with the lamivudine (single agent) after administration of the individual component.
Lamivudin u tableti s fiksnom kombinacijom doza bio je bioekvivalentan lamivudinu (pojedinačnom lijeku) primijenjenom samostalno.
Lamivudine is also available as an oral solution for children over three months of age and who weigh less than 14 kg or for patients who are unable to swallow tablets.
Lamivudin je dostupan i u obliku oralne otopine za djecu stariju od tri mjeseca i tjelesne težine manje od 14 kg ili za bolesnike koji ne mogu progutati tablete.
Lamivudine metabolism does not involve CYP3A, making interactions with medicinal products metabolised by this system (e.g.
Metabolizam lamivudina ne uključuje CYP3A, što znači da nisu vjerojatne interakcije s lijekovima koji se metaboliziraju putem tog sustava (npr. inhibitori proteaze).
Lamivudine monotherapy results in the selection of YMDD mutant HBV in approximately 24 % of patients following one year of therapy, increasing to 69 % following 5 years of therapy.
Monoterapija lamivudinom dovodi do selekcije YMDD tipa virusa u oko 24% bolesnika nakon godinu dana liječenja te se povećava na 69% nakon 5 godina liječenja.
Lamivudine monotherapy results in the selection of YMDD mutant HBV in approximately 24 % of patients following one year of therapy, increasing to 69 % following 5 years of therapy.
Monoterapija lamivudinom dovodi do selekcije YMDD tipa virusa u oko 24% bolesnika nakon godinu dana liječenja, te se povećava na 69% nakon 5 godina liječenja.
lamivudine PK ↔
lamivudin PK ↔
Lamivudine serum concentrations (AUC) are increased in patients with moderate to severe renal impairment due to decreased renal clearance.
Koncentracije lamivudina u serumu (AUC) povišene su u bolesnika s umjerenim do teškim oštećenjem bubrega zbog smanjenog bubrežnog klirensa.
Lamivudine Teva 100 mg
Lamivudin Teva 100 mg
Lamivudine Teva 100 mg film-coated tablets
Lamivudin Teva 100 mg filmom obložene tablete
Lamivudine Teva 100 mg film-coated tablets Lamivudine
Lamivudin Teva 100 mg filmom obložene tablete lamivudin
Lamivudine Teva and related medicines (NRTIs) may cause other conditions to develop during hepatitis B treatment.
Lamivudin Teva i slični lijekovi (NRTI) mogu uzrokovati razvoj drugih stanja tijekom liječenja infekcije hepatitisa B.
Lamivudine Teva can be taken with or without food.
Lamivudin Teva se može uzimati s hranom ili bez hrane.
Lamivudine Teva can be used during pregnancy if clinically needed.
Lamivudin Teva se može primijeniti tijekom trudnoće ukoliko je to klinički potrebno.
Lamivudine Teva can be used in people whose liver is damaged but still functions normally (compensated liver disease).
Lamivudin Teva se može primjenjivati u ljudi čija je jetra oštećena, ali još uvijek normalno funkcionira (kompenzirana bolest jetre).
Lamivudine Teva can pass into breast-milk.
Sastojci lijeka Lamivudin Teva mogu prijeći u majčino mlijeko.
Lamivudine Teva is an antiviral medicine that suppresses the hepatitis B virus and belongs to a group of medicines called nucleoside analogue reverse transcriptase inhibitors (NRTIs).
Lamivudin Teva je antivirusni lijek koji potiskuje virus hepatitisa B i pripada skupini lijekova koji se nazivaju nukleozidni analozi inhibitora reverzne transkriptaze (NRTI).
Lamivudine Teva is available in aluminium blisters containing 28, 30, 84 or 100 tablets or HDPE containers containing 60 tablets.
Lamivudin Teva dostupan je u aluminijskim blisterima koji sadrže 28, 30, 84 ili 100 tableta ili u spremnicima od polietilena visoke gustoće koji sadrže 60 tableta.
Lamivudine Teva is indicated for the treatment of chronic hepatitis B in adults with:
Lamivudin Teva je indiciran za liječenje kroničnog hepatitisa B u odraslih bolesnika s:
Lamivudine Teva is not suitable for patients who require doses below 100 mg.
Lamivudin Teva nije prikladan za bolesnike koji trebaju uzimati doze manje od 100 mg.
Lamivudine Teva is used to treat long term (chronic) hepatitis B infection in adults.
Lamivudin Teva se koristi u liječenju dugotrajne (kronične) infekcije hepatitisom B u odraslih bolesnika.
Lamivudine Teva may make you feel tired, which could affect your ability to drive or use machines.
Lamivudin Teva može uzrokovati umor, što može utjecati na sposobnost upravljanja vozilima i strojevima.
Lamivudine Teva Pharma B.V. 150 mg
Lamivudin Teva Pharma B.V. 150 mg
Lamivudine Teva Pharma B.V. 150 mg film-coated tablets
Lamivudin Teva Pharma B.V. 150 mg filmom obložene tablete
Lamivudine Teva Pharma B.V. 150 mg film-coated tablets Each film-coated tablet contains 150 mg lamivudine.
Lamivudin Teva Pharma B.V. 150 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 150 mg lamivudina.
Lamivudine Teva Pharma B.V. 150 mg film-coated tablets EU/1/09/596/001 20 tablets (blister)
Lamivudin Teva Pharma B.V. 150 mg filmom obložene tablete EU/1/09/596/001 20 tableta (blister)
Lamivudine Teva Pharma B.V. 150 mg film-coated tablets Lamivudine
Lamivudin Teva Pharma B.V. 150 mg filmom obložene tablete lamivudin
Lamivudine Teva Pharma B.V. 150 mg film-coated tablets: 50 ml container of 60 film-coated tablets.
Lamivudin Teva Pharma B.V. 150 mg filmom obložene tablete: spremnik od 50 ml s 60 filmom obloženih tableta.
Lamivudine Teva Pharma B.V. 300 mg
Lamivudin Teva Pharma B.V. 300 mg